KLBF, PEHA, KAEF, and INAF: A Performance Overview

KLBF, PEHA, KAEF, and INAF: A Performance Overview

Several listed companies have reported increases in sales and net profit, though many continue to face headwinds.

user-profile

Selasa, 12 Agustus 2025 | 10:50

Bisnis.com, JAKARTA — Sluggish domestic demand, higher prices for imported raw materials, and high operational costs have taken a toll on the performance of several pharmaceutical companies in H1/2025.

These challenges led to mixed financial results among Indonesia’s pharmaceutical issuers during the period, with some managing to post gains in sales and net profit, while others continued to struggle under the weight of rising expenses and tepid demand.

Bacaanmu terbatas?

Tenang, kamu hanya perlu Masuk atau Daftar dulu di sini untuk lanjut membaca Bisnis Indonesia Premium.

Nikmati Gratis Akses baca 3 artikel Bisnis Indonesia Premium bagi member baru!

atau langsung pilih paket terbaik kami:

banner-promo

faq

berita lainnya

To Top